Search results for " Sang"

showing 10 items of 268 documents

Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3‐year follow‐up of a multicenter, retrospective cli…

2022

: The combination of elotuzumab, lenalidomide, and dexamethasone (EloRd) enhanced the clinical benefit over Rd with a manageable toxicity profile in the ELOQUENT-2 trial, leading to its approval in relapsed/refractory multiple myeloma (RRMM). The present study is a 3-year follow-up update of a previously published Italian real-life RRMM cohort of patients treated with EloRd. This revised analysis entered 319 RRMM patients accrued in 41 Italian centers. After a median follow-up of 36 months (range 6-55), 236 patients experienced disease progression or died. Median progression-free survival (PFS) and overall survival (OS) were 18.4 and 34 months, respectively. The updated multivariate analyse…

Cancer Researchlenalidomidedexamethasone; elotuzumab; lenalidomide; multiple myeloma; salvage therapydexamethasoneHematologyGeneral MedicineAntibodies Monoclonal HumanizedelotuzumabThalidomidemultiple myelomaOncologyAntineoplastic Combined Chemotherapy ProtocolsHumanssalvage therapySettore MED/15 - Malattie del SangueFollow-Up StudiesRetrospective StudiesHematological Oncology
researchProduct

Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis. The ”CANCER DACUS” study

2014

Purpose We evaluated the role of residual vein thrombosis (RVT) to assess the optimal duration of anticoagulants in patients with cancer who have deep vein thrombosis (DVT) of the lower limbs. Patients and Methods Patients with active cancer and a first episode of DVT treated with low molecular weight heparin (LMWH) for 6 months were eligible. Patients were managed according to RVT findings: those with RVT were randomly assigned to continue LMWH for an additional 6 months (group A1) or to discontinue it (group A2), and patients without RVT stopped LMWH (group B). The primary end point was recurrent venous thromboembolism (VTE) during the 1 year after disconinuation of LMWH, and the secondar…

Cancer Researchmedicine.medical_specialtymedicine.drug_classDeep veinPopulationLow molecular weight heparinSettore MED/42 - Igiene Generale E ApplicataGroup BSettore MED/15 - Malattie Del SangueInternal medicineresidual vein thrombosis low molecular weight heparin cancer patientsmedicineeducationFirst episodeeducation.field_of_studybusiness.industrylow molecular weight heparinHazard ratioantivitamin K; low molecular weight heparin; nadroparinCancermedicine.diseaseThrombosisSurgerymedicine.anatomical_structureOncologynadroparinantivitamin Kbusiness
researchProduct

La caratterizzazione della Cardiomiopatia dilatativa mediante tecniche diagnostiche di primo e secondo livello.

2012

Cardiomiopatia dilatativaSettore MED/15 - Malattie Del Sangue
researchProduct

Le lenti del cavalleresco nel secondo Novecento

2012

Cavalleresco Calvino Manganelli Celati Bufalino Sanguineti Ronconi romance riscritture memoriaSettore L-FIL-LET/10 - Letteratura Italiana
researchProduct

Monocytes/macrophages but not T lymphocytes are the major targets of the CCL3/CCL4 chemokines produced by CD38(+)CD49d(+) chronic lymphocytic leukaem…

2010

ChemokineChronic lymphocytic leukemiaT-LymphocytesCCL3CD38Settore MED/08 - Anatomia PatologicaCD49dMonocytesMacrophages; Tumor Cells Cultured; Leukemia Lymphocytic Chronic B-Cell; Humans; Monocytes; Chemokine CCL4; Chemokine CCL3; T-LymphocytesTumor Cells CulturedMedicineMacrophageHumansChronicChemokine CCL4Chemokine CCL3CulturedLeukemiabiologybusiness.industryMonocyteMacrophagesB-CellHematologyT lymphocytemedicine.diseaseLeukemia Lymphocytic Chronic B-CellLymphocyticTumor Cellsmedicine.anatomical_structureImmunologybiology.proteinbusinessSettore MED/15 - Malattie del SangueCCL3/CCL4 CD38CD49d chronic lymphocitic leukemia
researchProduct

Inhibition of activated STAT5 in Bcr/Abl expressing leukemia cells with new pimozide derivatives.

2014

STATs are transcription factors acting as intracellular signaling after stimulation with cytokines, growth factors and hormones. STAT5 is also constitutively active in many forms of cancers, including chronic myelogenous leukemia, acute lymphoblastic leukemia and Hodgkin's lymphoma. Recently, literature reported that the neuroleptic drug pimozide inhibits STAT5 phosphorylation inducing apoptosis in CML cells. We undertook an investigation from pimozide structure, obtaining simple derivatives with cytotoxic and STAT5-inhibitory activity, two of them markedly more potent than pimozide.

Clinical BiochemistryFusion Proteins bcr-ablPharmaceutical ScienceApoptosisBiochemistrySettore MED/15 - Malattie Del SangueCell LineStructure-Activity RelationshipPimozideSettore BIO/13 - Biologia Applicatahemic and lymphatic diseasesDrug DiscoverymedicineSTAT5 Transcription FactorCytotoxic T cellHumansPhosphorylationMolecular BiologyTranscription factorSTAT5Cell ProliferationbiologyDose-Response Relationship DrugMolecular StructureChemistrySTAT5 inhibitorsPimozideBCR/ABL expressing leukemia ApoptosisCell growth inhibitionOrganic ChemistryCell CyclePimozidemedicine.diseaseSettore CHIM/08 - Chimica FarmaceuticaLeukemiaApoptosisCancer researchbiology.proteinSettore BIO/14 - FarmacologiaMolecular MedicinePhosphorylationK562 Cellsmedicine.drugChronic myelogenous leukemia
researchProduct

Autoantibody Inhibitor Eradication In Acquired Hemophilia Associated with Cancer: a Retrospective Analysis

2010

Abstract Abstract 1418 Introduction: Acquired hemophilia (AH), a rare autoimmune disorder primarily of adults, is typically characterized by the presence of IgG oligoclonal antibodies to the clotting factor VIII protein (FVIII). About 10–15% of patients with AH have an underlying malignancy, but the etiologic relationship of cancer to formation of FVIII inhibitor is yet to be determined. To date, there have been no published, comprehensive reviews on the efficacy of various treatments for AH in the context of either solid tumor or hematologic malignancies. Therefore, we have systematically reviewed 86 patients with cancer-associated AH from our own cancer center and from the published liter…

Clotting factoraCQUIRED HAEMOPHILIA INHIBITORSmedicine.medical_specialtyChemotherapybusiness.industrymedicine.medical_treatmentImmunologyAutoantibodyCancerContext (language use)Cell BiologyHematologyMalignancymedicine.diseaseBiochemistryGastroenterologyChemotherapy regimenSurgerySettore MED/15 - Malattie Del SangueProstate cancerInternal medicinemedicinebusiness
researchProduct

Dracocephalum ruyschiana L. (Ogres Kangari)

1977

Ruiša pūķgalve, atradne: Ogres rajonā, Ogres Kangaros, granstkarjera A galā priežu meža klajumiņā dienvidrietumu nogāzē, kopā ar Onobrychis, Geranium sanguineum, Filipendula hexapetala, Trifolium montanum (esparsete, asinssarkanā gandrene, lielziedu vīgrieze, kalnu āboliņš). /// Northern Dragon-head, deposit: In Ogre district, Ogres Kangaros, at the eastern end of the gravel quarry in the pine forest clearing on the south-west side, together with Onobrychis, Geranium sanguineum, Filipendula hexapetala, Trifolium montanum. [Attēls no LU Muzeja kolekcijas Herbarium Latvicum (RIG II); (BOT1029_7)]

Dracocephalum ruyschiananorthern Dragon-headOnobrychisTrifolium montanumGeranium sanguineumFilipendula hexapetalaKangari:NATURAL SCIENCES::Biology::Organism biology::Plant physiology [Research Subject Categories]ruiša pūķgalve
researchProduct

Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhi…

2014

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare disease of controversial origin recently recognized as a neoplasm deriving from plasmacytoid dendritic cells (pDCs). Nevertheless, it remains an orphan tumor with obscure biology and dismal prognosis. To better understand the pathobiology of BPDCN and discover new targets for effective therapies, the gene expression profile (GEP) of 25 BPDCN samples was analyzed and compared with that of pDCs, their postulated normal counterpart. Validation was performed by immunohistochemistry (IHC), whereas functional experiments were carried out ex vivo. For the first time at the molecular level, we definitely recognized the cellular derivati…

EXPRESSIONMyeloidCancer ResearchPathologymedicine.medical_specialtyMyeloidCell Cycle; Dendritic Cells; Humans; Leukemia Myeloid Acute; NF-kappa B; Signal Transduction; Gene Expression Profiling; Hematology; Cancer Research; Anesthesiology and Pain MedicineAcuteBiologyCell Cycle; Dendritic Cells; Humans; Leukemia Myeloid Acute; NF-kappa B; Signal Transduction; Gene Expression ProfilingDendritic CellArticleMALIGNANCIESMULTIPLE-MYELOMABlastic plasmacytoid dendritic cell neoplasmBlastic plasmacytoid dendritic cell neoplasm; anti-NF-kB-treatment; GEPGene expressionmedicineHumansNeoplasmanti-NF-kB-treatmentGene Expression ProfilingCell CycleNF-kappa BleukemiaIN-VITRODendritic CellsHematologyBlastic plasmacytoid dendritic cell neoplasmmedicine.diseaseCANCERGEPFACTOR-KAPPA-BLeukemia Myeloid AcuteSettore MED/15 - MALATTIE DEL SANGUEDIFFERENTIATIONAnesthesiology and Pain Medicinemedicine.anatomical_structureLYMPHOID PATHWAYSOncologyCell cultureHEMATODERMIC NEOPLASMImmunohistochemistryCellular modelEx vivoHumanSignal Transduction
researchProduct

The Exosomes-derived EGFR Ligand Amphiregulin (AREG) is a new key player in Multiple Myeloma Bone Destruction

Il Mieloma Multiplo (MM) è caratterizzato dalla presenza di aree osteolitiche dovute alla presenza di plasmacellule (PC) neoplastiche che causano l'interruzione della normale omeostasi ossea, promuovendo l'attività degli osteoclasti (OC) ed inibendo la funzione degli (OB). Al momento, uno dei campi di ricerca nella fisiopatologia del MM è proprio lo studio dei meccanismi che regolano l’attività degli OC e degli OB così come l’identificazione di target terapeutici per la prevenzione ed il trattamento delle lesioni osteolitiche. Negli ultimi anni è emerso che le vescicole extracellulari (EV), ed in particolare gli esosomi, giocano un ruolo fondamentale nel mediare il cross-talk tra le cellule…

ExosomeEpidermal growth factor receptorMultiple myelomaSettore BIO/13 - Biologia ApplicataBone diseaseInterleukin 8AmphiregulinSettore MED/15 - Malattie Del Sangue
researchProduct